SCHEMBL2643391

SCHEMBL2643391

CCOC(=O)CC(=O)c1cc(C(F)(F)F)ccc1OCC

nearest known ligand 0.55

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP1A2 P05177 2/20 0.55
CYP2C19 P33261 2/20 0.55
CYP2C9 P11712 1/20 0.55
L3MBTL1 Q9Y468 3/20 0.46
ALDH1A1 P00352 2/20 0.46
GAA P10253 2/20 0.46
RXFP1 Q9HBX9 1/20 0.45
SCN8A Q9UQD0 2/20 0.44
SCN10A Q9Y5Y9 2/20 0.44
MRGPRX4 Q96LA9 1/20 0.43
NPSR1 Q6W5P4 1/20 0.43
CETP P11597 1/20 0.42
MEN1 O00255 1/20 0.42
CYP3A4 P08684 1/20 0.42
KMT2A Q03164 1/20 0.42
MAPT P10636 2/20 0.42
NPC1 O15118 1/20 0.41
RAB9A P51151 1/20 0.41
SMN1; SMN2 Q16637 1/20 0.41
POLB P06746 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2642926 0.90 ALDH1A1 (0.50) CYP1A2CYP2C19CYP2C9L3MBTL1ALDH1A1
SCHEMBL2645532 0.84 NPSR1 (0.45) CYP1A2CYP2C19CYP2C9L3MBTL1ALDH1A1
SCHEMBL983425 0.83 CYP1A2 (0.57) CYP1A2CYP2C19CYP2C9L3MBTL1ALDH1A1
SCHEMBL30953612 0.81 NPSR1 (0.45) CYP1A2CYP2C19CYP2C9L3MBTL1ALDH1A1
SCHEMBL477612 0.80 CYP2C19 (0.59) CYP1A2CYP2C19CYP2C9L3MBTL1ALDH1A1
SCHEMBL477642 0.79 CYP2C19 (0.58) CYP1A2CYP2C19CYP2C9L3MBTL1ALDH1A1
SCHEMBL5277497 0.79 ESR1 (0.50) CYP1A2CYP2C19CYP2C9ALDH1A1MRGPRX4
SCHEMBL19782877 0.77 L3MBTL1 (0.56) CYP1A2CYP2C19CYP2C9L3MBTL1ALDH1A1
SCHEMBL16958277 0.77 CYP2C19 (0.58) CYP1A2CYP2C19CYP2C9L3MBTL1ALDH1A1
SCHEMBL11339085 0.76 HCRTR1 (0.58) L3MBTL1ALDH1A1GAAMEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1940799-A1 PYRAZOLE DERIVATIVES, COMPOSITIONS CONTAINING SUCH COMPOUNDS AND METHODS OF USE Merck & Co., Inc. (US) 2008-07-09 EP disclosed
WO-2007047676-A1 PYRAZOLE DERIVATIVES, COMPOSITIONS CONTAINING SUCH COMPOUNDS AND METHODS OF USE MERCK & CO., INC. (US) 2007-04-26 WO disclosed
US-20070088070-A1 Pyrazole derivatives, compositions containing such compounds and methods of use PARMEE EMMA R 2007-04-19 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070088070-A1 Pyrazole derivatives, compositions containing such compounds and methods of use PC, GOT2, PNLIP CYP1A2 84/4885CYP2C19 228/4885CYP2C9 337/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.